Yahong Pharmaceuticals: APL-1401 obtained positive preliminary results in Phase Ib clinical trial for treatment of moderate to severe active ulcerative colitis.

date
03/08/2025
Yahong Pharmaceuticals announced on the evening of July 31 that the Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis has achieved positive preliminary results. Based on the positive results obtained from this study, the company plans to further evaluate the efficacy of this potential first-in-class therapy in a larger population of patients with moderate to severe active ulcerative colitis over a 12-week treatment period, providing more comprehensive supportive evidence for future clinical research and hoping to provide new treatment options for patients in the future.